AACE Task Force for the Management of Dyslipidemia and Prevention of Atherosclerosis Writing Committee

被引：61
作者：
Jellinger, Paul S.
Smith, Donald A.
Mehta, Adi E.
Ganda, Om
Handelsman, Yehuda
Rodbard, Helena W.
Shepherd, Mark D.
Seibel, John A.
机构：
来源：
ENDOCRINE PRACTICE | 2012年 / 18卷 / 02期
关键词：
CORONARY-HEART-DISEASE; PRIMARY HYPERCHOLESTEROLEMIA; CARDIOVASCULAR-DISEASE; GEMFIBROZIL TREATMENT; METABOLIC SYNDROME; PLASMINOGEN-ACTIVATOR; MYOCARDIAL-INFARCTION; AMERICAN ASSOCIATION; DIABETES-MELLITUS; SERUM-CHOLESTEROL;
D O I：
10.4158/EP.18.2.269
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：270 / 293
页数：24
相关论文
共 100 条
  • [1] Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias:: An open-label, multicenter study
    Aguilar-Salinas, CA
    Fanghänel-Salmón, G
    Meza, E
    Montes, J
    Gulías-Herrero, A
    Sánchez, L
    Monterrubio-Flores, EA
    González-Valdez, H
    Pérez, FJG
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2001, 50 (06): : 729 - 733
  • [2] Standards of Medical Care in Diabetes-2009
    不详
    [J]. DIABETES CARE, 2009, 32 : S13 - S61
  • [3] American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee, 2005, Endocr Pract, V11, P126
  • [4] [Anonymous], 1992, Pediatrics, V89, P525
  • [5] [Anonymous], 2011, LIV PIT
  • [6] [Anonymous], 2004, 7 REP JOINT NAT COMM
  • [7] [Anonymous], 2011, PRAV PRAV SOD
  • [8] [Anonymous], 2006, COL COL HYDR
  • [9] [Anonymous], 2008, LOP GEMF
  • [10] [Anonymous], 2010, MEV
12345678910